Direct Oral Anticoagulants for Stroke Prevention in Special Populations: Beyond the Clinical Trials

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Direct oral anticoagulants (DOACs) are first-line therapy for non-valvular atrial fibrillation (NVAF).
• DOACs offer improved safety over warfarin, particularly regarding intracranial bleeding.
• Previous DOAC trials excluded specific patient groups common in clinical practice.

Purpose of the Study:

• To review the efficacy and safety of DOACs in elderly, obese, underweight, frail, and cancer patients with NVAF.
• To evaluate DOAC use in patients with bioprosthetic heart valves and NVAF.
• To clarify optimal anticoagulant strategies for these understudied NVAF subpopulations.

Main Methods:

• Systematic literature review.
• Analysis of randomized controlled trials and observational studies.
• Focus on efficacy (stroke prevention) and safety (bleeding events).

Main Results:

• Evidence for DOACs in special NVAF populations is limited and often extrapolated.
• DOACs' safety and efficacy in elderly, obese, underweight, frail, and cancer patients require further investigation.
• Data on DOACs in patients with bioprosthetic heart valves remain scarce and controversial.

Conclusions:

• Current DOAC guidelines may not fully apply to diverse clinical populations with NVAF.
• Further research is crucial to establish evidence-based anticoagulant strategies for these specific NVAF groups.
• Optimizing DOAC use in these subpopulations is essential for improving patient outcomes.